Clinical application of a lectin-antibody ELISA to measure fucosylated haptoglobin in sera of patients with pancreatic cancer

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 4, 2010, Pages 505-512

  Matsumoto, Hitoshi ^a   Shinzaki, Shinichiro ^a   Narisada, Megumi ^a   Kawamoto, Sayuri ^a   Kuwamoto, Kana ^a   Moriwaki, Kenta ^a   Kanke, Futoshi ^b   Satomura, Shinji ^b   Kumada, Takashi ^c   Miyoshi, Eiji ^a  

^a OSAKA UNIVERSITY   (Japan)

^b FUJIFILM Wako Pure Chemical Corporation   (Japan)

^c OGAKI MUNICIPAL HOSPITAL   (Japan)

Author keywords

Fucosylation; Lectin antibody ELISA; Oligosaccharide; Pancreatic cancer

Indexed keywords

HAPTOGLOBIN; IMMUNOGLOBULIN F(AB) FRAGMENT; LECTIN; PHYTOHEMAGGLUTININ ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CHRONIC PANCREATITIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DOUBLE ANTIBODY SANDWICH ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FUCOSYLATION; HUMAN; IMMUNOASSAY; IMMUNOPRECIPITATION; MAJOR CLINICAL STUDY; MEASUREMENT; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOTTING; SENSITIVITY AND SPECIFICITY;

ANTIBODIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HAPTOGLOBINS; HUMANS; LECTINS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

ALEURIA AURANTIA;

EID: 77949828637     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.095     Document Type: Article

References (22)

1. Dwek RA, Edge CJ, Harvey DJ, Wormald MR, Parekh RB. Analysis of glycoprotein-associated oligosaccharides. Annu Rev Biochem 1993;62:65-100.
2. Fukuda M. Possible roles of tumor-associated carbohydrate antigens. Cancer Res 1996;56:2237-2244 Review.
3. Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology 1990;12:1420-1432
4. Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, Taga H, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 1993;53:5419-5423
5. Food and Drug Administration, HHS. Medical devices; immunology and microbiology devices; classification of AFP-L3% immunological test systems. Final rule. Fed Regist 2005;70: 57748-57750
6. Kagebayashi C, Yamaguchi I, Akinaga A, Kitano H, Yokoyama K, Satomura M, et al. Automated immunoassay system for AFP-L3% using on-chip electrokinetic reaction and separation by affinity electrophoresis. Anal Biochem 2009;388:306-311
7. Block TM, Comunale MA, Lowman M, Steel LF, Romano PR, Fimmel C, et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA 2005;102: 779-784
8. Wang M, Long RE, Comunale MA, Junaidi O, Marrero J, Di Bisceglie AM, et al. Novel fucosylated biomarkers for the early detection of hepatocellular carcinoma. Cancer Epidem Biomar Prev 2009;18:1914-1921
9. Doi R, Imamura M, Hosotani R, Imaizumi T, Hatori T, Takasaki K, et al. Japan Pancreatic Cancer Study Group. Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial. Surg Today 2008;38:1021-1028
10. Ueno H, Kosuge T. Adjuvant treatments for resectable pancreatic cancer. J Hepatobiliary Pancreat Surg 2008;15:468-472
11. Ueno H, Kosuge T, Matsuyama Y, Yamamoto J, Nakao A, Egawa S, et al. A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer. Br J Cancer 2009;101:908-915
12. Okuyama N, Ide Y, Kawano S, Gu J, Taniguchi N, Miyoshi E, et al. Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 2006;118: 2803-2808
13. Zhao J, Patwa TH, Qiu W, Shedden K, Hinderer R, Misek DE, et al. Glycoprotein microarrays with multi-lectin detection: unique lectin binding patterns as a tool for classifying normal, chronic pancreatitis and pancreatic cancer sera. J Proteome Res 2007;6:1864-1874
14. Ang IL, Poon TC, Lai PB, Chan AT, Ngai SM, Hui AY, et al. Study of serum haptoglobin and its glycoforms in the diagnosis of hepatocellular carcinoma: a glycoproteomic approach. J Proteome Res 2006;5:2691-2700
15. Fujimura T, Shinohara Y, Tissot B, Pang PC, Kurogochi M, Saito S, et al. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects. Int J Cancer 2008;122:39-49.
16. Ueda K, Katagiri T, Shimada T, Irie S, Sato TA, Nakamura Y, et al. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer. J Proteome Res 2007;6: 3475-3483
17. Turner GA. Haptoglobin. A potential reporter molecule for glycosylation changes in disease. Adv Exp Med Biol 1995;376: 231-238
18. Dobryszycka W. Haptoglobin: retrospectives and perspectives. Boca Raton: CRC Press, 1993.
19. Narisada M, Nakagawa T, Matsumoto H, Asahi M, Koyama N, Miyoshi E, et al. Identification of an inducible factor secreted by pancreatic cancer cell lines that stimulates the production of fucosylated haptoglobin in hepatoma cells. Biochem Biophys Res Commun 2008;377:792-796
20. Miyoshi E, Nakano M. Fucosylated haptoglobin is a novel marker for pancreatic cancer: detailed analyses of oligosaccharide structures. Proteomics 2008;8:3257-3262
21. Nakano M, Nakagawa T, Ito T, Kitada T, Taniguchi N, Miyoshi E, et al. Site-specific analysis of N-glycans on haptoglobin in sera of patients with pancreatic cancer: a novel approach for the development of tumor markers. Int J Cancer 2008;122: 2301-2309
22. Balagopal A, Philp FH, Astemborski J, Block TM, Mehta A, Long R, et al. Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008;135:226-233